烟台起家的绿叶制药,在中枢神经系统(CNS)领域开始风生水起。 11月28日,首个中国制抗抑郁化药1类创新药若欣林,纳入2024年国家医保药品目录,同时纳入的还有两款抗癌药物。 “我们期待通过纳入医保,让该药品惠及更多患者。” 绿叶制药(中国)CNS事业部负责人陈哲告诉《21CBR》记者,过去两年,该药收到临床良好的反馈,只是部分患者受限于自费药价格,无法受益。 6月以来,绿叶接连获批上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.